Open Label Comparison of Injectable Buprenorphine ( Brixadi®) and Naltrexone (Vivitrol®) for Opioid Use Disorder
Sponsor: University of Pennsylvania
Terminated
Primary funding source has ended.
Other terminated trials from University of Pennsylvania
Other Opioid Use Disorder trials with similar outcome
Listed as NCT05596955, this PHASE2 trial focuses on Opioid Use Disorder and remains terminated or withdrawn. Sponsored by University of Pennsylvania, it has been updated 8 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Apr 2025 — Present [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Sep 2024 — Apr 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Mar 2023 — Mar 2024 [monthly]
Recruiting PHASE2
▶ Show 3 earlier versions
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2023 — Feb 2023 [monthly]
Not Yet Recruiting PHASE2
-
Nov 2022 — Jan 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Aug 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Pennsylvania
For direct contact, visit the study record on ClinicalTrials.gov .